Recent News

• 03.17.2026 - New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
• 03.16.2026 - New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
• 03.02.2026 - Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

Recent Filings

• 03.17.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.16.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.09.2026 - 144 Report of proposed sale of securities
• 03.06.2026 - 144 Report of proposed sale of securities
• 03.06.2026 - 144/A Report of proposed sale of securities
• 03.05.2026 - 144 Report of proposed sale of securities
• 03.05.2026 - 144 Report of proposed sale of securities
• 03.05.2026 - 144 Report of proposed sale of securities
• 03.04.2026 - 144 Report of proposed sale of securities